脾氨肽治疗小儿反复呼吸道感染临床疗效观察.docVIP

脾氨肽治疗小儿反复呼吸道感染临床疗效观察.doc

  1. 1、原创力文档(book118)网站文档一经付费(服务费),不意味着购买了该文档的版权,仅供个人/单位学习、研究之用,不得用于商业用途,未经授权,严禁复制、发行、汇编、翻译或者网络传播等,侵权必究。。
  2. 2、本站所有内容均由合作方或网友上传,本站不对文档的完整性、权威性及其观点立场正确性做任何保证或承诺!文档内容仅供研究参考,付费前请自行鉴别。如您付费,意味着您自己接受本站规则且自行承担风险,本站不退款、不进行额外附加服务;查看《如何避免下载的几个坑》。如果您已付费下载过本站文档,您可以点击 这里二次下载
  3. 3、如文档侵犯商业秘密、侵犯著作权、侵犯人身权等,请点击“版权申诉”(推荐),也可以打举报电话:400-050-0827(电话支持时间:9:00-18:30)。
  4. 4、该文档为VIP文档,如果想要下载,成为VIP会员后,下载免费。
  5. 5、成为VIP后,下载本文档将扣除1次下载权益。下载后,不支持退款、换文档。如有疑问请联系我们
  6. 6、成为VIP后,您将拥有八大权益,权益包括:VIP文档下载权益、阅读免打扰、文档格式转换、高级专利检索、专属身份标志、高级客服、多端互通、版权登记。
  7. 7、VIP文档为合作方或网友上传,每下载1次, 网站将根据用户上传文档的质量评分、类型等,对文档贡献者给予高额补贴、流量扶持。如果你也想贡献VIP文档。上传文档
查看更多
脾氨肽治疗小儿反复呼吸道感染临床疗效观察

脾氨肽治疗小儿反复呼吸道感染临床疗效观察   【摘要】 目的:分析探讨脾氨肽(复可托)治疗反复呼吸道感染的临床疗效。方法:选取本院近年来收治的60例反复呼吸道感染患者作为研究对象,按照数字抽签法将其随机分为研究组与对照组,每组30例,研究组在常规治疗的基础上行复可托治疗,对照组仅行常规治疗,比较两组治疗效果。结果:研究组治疗显效率为56.7%,总有效率为90.0%,对照组治疗显效率为23.3%,总有效率为50.0%,研究组患者治疗效果明显优于对照组(P0.05)。与治疗前相比,研究组患者治疗后CD8指标出现明显下降,CD3、CD4、CD4/CD8指标出现明显上升,治疗前后研究组患者T细胞亚群指标比较差异有统计学意义(P0.05)。结论:复可托治疗反复呼吸道感染可改善患者免疫失衡状态,具有显著的临床疗效。   【关键词】 脾氨肽; 小儿反复呼吸道感染; 免疫失衡   Clinical Observation Spleen Aminopeptidase (Stoeckel care) Treatment of Recurrent Respiratory Tract Infections/ZENG Sheng-rong, DING Shu-juan.//Medical Innovation of China,2014,11(28):076-079   【Abstract】 Objective: To investigate the spleen ammonia peptide (complex) clinical curative effect for the treatment of recurrent respiratory tract infections. Method: To select 60 patients admitted in our hospital in recent years, patients with recurrent respiratory tract infections as the research object, according to the digital lottery method were randomly divided into research group and control group, 30 cases in each group, the team in uplink compound could be the basis of routine therapy treatment, the control group only routine treatment, compare therapeutic effect of the two groups. Result: Team treatment efficiency was 56.7%, total effective rate was 90.0%, the control group’s treatment efficiency was 23.3%, total effective rate was 50.0%, the team with the treatment effect was better than the control group (P0.05). Compared with before treatment, the team CD8 index after treatment in patients with decreased obviously, CD3, CD4, CD4 / CD8 indicators appeared obvious rise, before and after treatment group patients with T cell subgroup index comparison difference was statistically significant (P0.05). Conclusion: Compound can improve the patients immune treatment of recurrent respiratory tract infections is imbalance, has significant clinical effect.   【Key words】 Spleen aminopeptidase; Recurrent respiratory infections; Immune imbalance   First-author’s address: The First Peoples

文档评论(0)

189****7685 + 关注
实名认证
文档贡献者

该用户很懒,什么也没介绍

1亿VIP精品文档

相关文档